Dr. Nyati is a professor in the Department of Radiation Oncology at the University of Michigan, with over 30 years of expertise in basic and translational oncology. He is actively involved in academic education, research, and peer review for top-tier journals and funding agencies such as the NIH. An avid photographer and dedicated cancer awareness volunteer, his work is funded by agencies including the NIH and DoD. Dr. Nyati has obtained numerous international patents for his contributions to the development of novel anti-cancer agents and has been involved in several biotech startups.

The main focus of Dr. Nyati's research is investigating the role of protein stability in cancer progression and treatment. He has been extensively studying key oncogenes such as EGFR, BRAF, and KRAS, aiming to develop agents that induce the selective degradation of activated EGFR. Additionally, he explores the functions of the EGFR protein that are independent of its kinase activity, particularly its role in cell survival. Dr. Nyati is also part of the Protein Folding Disease Initiative Group, where he investigates the roles of Hsp90 chaperone machinery in DNA repair. His comprehensive research continues to contribute significantly to the field of cancer research.